Quantitative facial expression analysis revealed the efficacy and time course of oxytocin in autism.
Discrepancies in efficacy between single-dose and repeated administration of oxytocin for autism spectrum disorder have led researchers to hypothesize that time-course changes in efficacy are induced by repeated administrations of the peptide hormone. However, repeatable, objective, and quantitative...
| Publicado en: | Brain: A Journal of Neurology Vol. 142; no. 7; pp. 2127 - 2137 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Oxford University Press / USA
Jul2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137291002&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 137291002 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00068950 2RY jtl: Brain: A Journal of Neurology issn: 00068950 maglogo: N pubinfo: dt: Jul2019 vid: 142 iid: 7 pid: 622 pub: Oxford University Press / USA artinfo: ui: 137291002 137291002 NLM31096266 137291002 10.1093/brain/awz126 NLM31096266 137291002 ppf: 2127 ppct: 10 formats: tig: atl: Quantitative facial expression analysis revealed the efficacy and time course of oxytocin in autism. aug: au: Owada, Keiho Okada, Takashi Munesue, Toshio Kuroda, Miho Fujioka, Toru Uno, Yota Matsumoto, Kaori Kuwabara, Hitoshi Mori, Daisuke Okamoto, Yuko Yoshimura, Yuko Kawakubo, Yuki Arioka, Yuko Kojima, Masaki Yuhi, Teruko Yassin, Walid Kushima, Itaru Benner, Seico Ogawa, Nanayo Kawano, Naoko affil: Department of Child Neuropsychiatry, School of Medicine, The University of Tokyo, 7–3–1 Hongo, Bunkyo-ku, Tokyo, Japan Department of Pediatrics, The University of Tokyo Hospital, 7–3–1 Hongo, Bunkyo-ku, Tokyo, Japan sug: subj: Oxytocin Administration and Dosage Oxytocin Therapeutic Use Facial Expression Interpersonal Relations Male Human Double-Blind Studies Young Adult Crossover Design Adult Adolescence Time Factors Administration, Intranasal Middle Age Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Random Assignment Adult: 19-44 years Adolescent: 13-18 years Middle Aged: 45-64 years Male ab: Discrepancies in efficacy between single-dose and repeated administration of oxytocin for autism spectrum disorder have led researchers to hypothesize that time-course changes in efficacy are induced by repeated administrations of the peptide hormone. However, repeatable, objective, and quantitative measurement of autism spectrum disorder's core symptoms are lacking, making it difficult to examine potential time-course changes in efficacy. We tested this hypothesis using repeatable, objective, and quantitative measurement of the core symptoms of autism spectrum disorder. We examined videos recorded during semi-structured social interaction administered as the primary outcome in single-site exploratory (n = 18, crossover within-subjects design) and multisite confirmatory (n = 106, parallel-group design), double-blind, placebo-controlled 6-week trials of repeated intranasal administrations of oxytocin (48 IU/day) in adult males with autism spectrum disorder. The main outcomes were statistical representative values of objectively quantified facial expression intensity in a repeatable part of the Autism Diagnostic Observation Schedule: the maximum probability (i.e. mode) and the natural logarithm of mode on the probability density function of neutral facial expression and the natural logarithm of mode on the probability density function of happy expression. Our recent study revealed that increases in these indices characterize autistic facial expression, compared with neurotypical individuals. The current results revealed that oxytocin consistently and significantly decreased the increased natural logarithm of mode on the probability density function of neutral facial expression compared with placebo in exploratory (effect-size, -0.57; 95% CI, -1.27 to 0.13; P = 0.023) and confirmatory trials (-0.41; -0.62 to -0.20; P < 0.001). A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001). Post hoc analyses revealed maximum efficacy at 2 weeks (P < 0.001, Cohen's d = -0.78; 95% CI, -1.21 to -0.35) and deterioration of efficacy at 4 weeks (P = 0.042, Cohen's d = -0.46; 95% CI, -0.90 to -0.01) and 6 weeks (P = 0.10, Cohen's d = -0.35; 95% CI, -0.77 to 0.08), while efficacy was preserved at 2 weeks post-treatment (i.e. 8 weeks) (P < 0.001, Cohen's d = -1.24; 95% CI, -1.71 to -0.78). Quantitative facial expression analyses successfully verified the positive effects of repeated oxytocin on autistic individuals' facial expressions and demonstrated a time-course change in efficacy. The current findings support further development of an optimized regimen of oxytocin treatment. pubtype: Academic Journal doctype: research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|